Shop

Author at Microdose

Madison Roberts

Madison Roberts is a nomadic journalist exploring the intersections of cutting-edge science, tech and human well-being. She immerses in diverse cultures, uncovering compelling stories in biotech, neuropsychiatry, neuroscience, mental health, psychedelics and longevity research. Her writing blends scientific rigor with human narratives, resonating across readers. Passionate about the brain's intricacies and psychedelics' healing potential, she's a thought-provoking, empathetic storyteller. Between interviews and breakthroughs, Madison cherishes tranquil moments exploring new landscapes.

Breaking News, Press Releases, Science

3 Jun 2025

Enveric’s Patent Win Targets New Frontiers in Sleep Medicine

With U.S. Patent No. 12,187,679 now granted, Enveric Biosciences has secured more than intellectual property—it’s staked a claim on the future of neurotherapeutics. The Cambridge-based biotech firm announced this week...

By Madison Roberts

Industry

20 May 2025

Enveric Biosciences Stakes Its Claim in Neurodegeneration Market

Enveric Biosciences is quietly making a bold move into the neurodegenerative disease space with a new class of molecules targeting the critical BDNF/TrKB pathway. While still in early stages, this...

By Madison Roberts

Health & Wellness

19 May 2025

Healing Beyond Addiction: New Research Shows Family Relationships Key to Lasting Recovery

Family healing plays a critical role in overcoming addiction, increasing recovery success rates by up to 50%. Despite this, a severe shortage of mental health professionals leaves many Texans without...

By Madison Roberts

Science

8 May 2025

A Psychedelic Turning Point: How a Landmark Review Re‑frames Psilocybin’s Role in Treating Addiction

Groundbreaking analysis of every modern clinical study on psilocybin for substance‑use disorders shows the psychedelic, when delivered with structured therapy, can dramatically cut drinking and smoking rates and sustain long‑term...

By Madison Roberts

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

8 Apr 2025

No More Silence: The Opioid Epidemics Alarming Impact on Women

Women are facing a silent crisis in the opioid epidemic, with overdose deaths among women aged 30–64 skyrocketing by 260% since 1999. Beyond the statistics lie the stories of mothers,...

By Madison Roberts

Industry, Psychedelic Titans, Science

31 Mar 2025

The Future of Psychedelics: Why Next-Generation Molecules Will Win

The psychedelic industry is undergoing a major transformation. With new, non-hallucinogenic compounds on the rise, companies like Enveric Biosciences, Delix Therapeutics, and Gilgamesh Pharmaceuticals are leading the way in developing...

By Madison Roberts

Breaking News, Finance, Press Releases

25 Feb 2025

Enveric Biosciences’ Patent For Non-Hallucinogenic Psychedelic Compounds

Enveric Biosciences (NASDAQ: ENVB) has received its first U.S. patent for the EVM401 Series, a collection of non-hallucinogenic compounds derived from mescaline. These novel therapeutics target multiple neurological receptors associated...

By Madison Roberts

Culture, Healing, Health & Wellness

5 Feb 2025

Microdosing & Women’s Hormones: A Revolutionary Approach to Healing

For too long, women’s health has been reduced to symptom management—birth control, hormone patches, and endless supplements. But what if true healing isn’t about masking symptoms, but restoring balance at...

By Madison Roberts

Breaking News

4 Feb 2025

A New Horizon in Joint Disease Treatment: Enveric Biosciences and Restoration Biologics Forge Licensing Agreements

Enveric Biosciences has entered into a licensing agreement with Restoration Biologics to develop and commercialize cannabinoid-COX-2 conjugate compounds, promising a new frontier in joint disease treatment. This partnership could redefine...

By Madison Roberts

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

You Might Also Like

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts

10 Oct 2025

After the Billion-Dollar Psychedelic Bet: Who’s Next for Big Pharma?

In the wake of Gilgamesh’s billion-dollar exit, a new wave of companies is emerging, smaller, stealthier, and far more scientifically disciplined than their first-wave predecessors. Their mission: harness the therapeutic...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.